Elevar Therapeutics Acquires Global Rights to European Approved Apealea® from Oasmia Pharmaceutical
- Wednesday, March 25, 2020, 5:21
- Business
- Add a comment
SALT LAKE CITY, March 25, 2020 /PRNewswire/ — Elevar Therapeutics, Inc., a fast-growing biopharmaceutical company focused on promising therapies for unmet medical needs in cancer, announced today an agreement with Swedish-based Oasmia Pharmaceutical AP to obtain global rights for…
About the Author
adminasapcorp has written 39063 stories on this site.